Navigation Links
LifeCare Holdings, Inc. Announces Year-end Results
Date:3/28/2008

PLANO, Texas, March 28 /PRNewswire/ -- LifeCare Holdings, Inc. (the "Company") today announced its operating results for the three months and year ended December 31, 2007.

Three Months Ended December 31, 2007

Net Revenues

Our net patient service revenue of $79.7 million for the three months ended December 31, 2007, decreased by $0.1 million as compared to the same period in 2006. Patient days increased by 1,027, or 1.8%, and admissions increased by 32, or 1.5%, during the 2007 period. During the three months ended December 31, 2007, our net patient service revenue per patient day was $1,390 as compared to $1,416 per patient day for the same period in 2006, which represents a decrease of 1.8%. This decrease on a per patient day basis was primarily the result of the recent unfavorable reimbursement changes implemented by CMS during 2007, partially offset by an increase in the percentage of our revenues generated from commercial payors.

Expenses

Total expenses increased by $17.1 million to $117.4 million for the three months ended December 31, 2007 as compared to $100.3 million for the comparable period in 2006. Included in expenses for the 2007 and 2006 periods are impairment charges of $35.0 million and $19.0 million, respectively. Excluding the impairment charges, expenses increased by $1.1 million to $82.4 million for the 2007 period as compared to $81.3 million for the 2006 period.

Rent expense increased by $1.4 million during the 2007 period in connection with an 11.5% increase in average licensed bed capacity. The provision for doubtful accounts decreased by $2.9 million during the 2007 period as compared to the same period in 2006 due primarily to a $1.7 million charge for the impact of a conversion to a new patient accounting system during the 2006 period.

Net interest expense increased by $1.2 million during the 2007 period as the result of the increase in LIBOR rates during 2007 and the increased margin
'/>"/>

SOURCE LifeCare Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. LifeCare Hospitals of Wisconsin Unveils Center for Advanced Wound Healing
2. LifeCare Holdings, Inc. Announces Third Quarter Results
3. Batesville Holdings, Inc., Appoints Doug Wilson Senior Vice President Human Resources
4. Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings, Inc. Prompt Notice of Noncompliance from the Nasdaq Global Market
5. Solera Holdings, Inc. Appoints Jason Brady as General Counsel
6. Duane Reade Holdings, Inc. to Report Fourth Quarter and Full Year 2007 Financial Results
7. Whitemark Homes Signs Letter of Intent to Acquire Metiscan Holdings, Inc.
8. Vallon Holdings, LLC Launches New Subsidiary Focused on Contract Resources for the Minneapolis-St. Paul Life Science Industry
9. NightHawk Radiology Holdings, Inc. Announces Board Member Departure
10. NightHawk Radiology Holdings, Inc. to Speak at the Cowen and Company 28th Annual Health Care Conference on March 18, 2008
11. Lixte Biotechnology Holdings, Inc. Announces Further Developments Regarding the Anti-Cancer Activity of Its Patent-Pending Proprietary Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)...ADENA, Calif., May 9 /PRNewswire-FirstCall/ -- Aut...rted a net loss of $107,000, or ($0.01) per,share ...h 31, 2008,compared with net income of $8,000, or...hree months ended March 31, 2007. As of March 31, ...d marketable securities as,compared to $8.8 millio...
(Date:5/9/2008)...e to Reporters/Editors: Next week, May 11-17, is N...ssued a proclamation honoring Texas,hospitals., ...s hospitals across the,country prepare to celebrat...ital Association is emphasizing patient-focused re...a new section on advance directives.,Consumers can...
(Date:5/9/2008)...ENIX, May 9 /PRNewswire/ -- CIGNA HealthCare of Ar...unced that effective immediately, CIGNA plan,membe... care provided by,Catholic Healthcare West facilit...althcare West,s three Arizona hospitals, including...r Regional Medical Center, Mercy,Gilbert Medical C...
(Date:5/9/2008)...udy finds overall 25% drop in those who take up th...s) -- Training influential students to spread anti...with peers helps reduce smoking rates, according t...11,000 students, ages 12 to 13, at 59 schools in w...rtain students were selected to receive training a...
Breaking Medicine News(10 mins):Health News:AutoImmune Inc. Reports 2008 First Quarter Financial Results 2Health News:AutoImmune Inc. Reports 2008 First Quarter Financial Results 3Health News:Web Site Helps Patients Prepare for Hospital Stay 2Health News:Web Site Helps Patients Prepare for Hospital Stay 3Health News:CIGNA HealthCare of Arizona and Catholic Healthcare West Reach Agreement 2Health News:Training Student Leaders Cuts Peers' Smoking Rates 2
... is only too happy to perform it. Nathan aged 13...sed with X-linked lymphoproliferative syndrome, //... lymphoproliferative syndrome has affected around ... Life expectancy is very low in those diagnosed wi...
...ntreats policy makers to target older adults in ad...ns to combat binge drinking. // Binge drinking h...s. Binge drinking can be described as consuming 1...e go for men and seven or more for women. Accordi...
...e a calendar-like printout every time a prescripti...al therapist and associate dean, who wanted to red.... // Multiple prescriptions can be confusing: know...at medication and what pills have special instruct...
...ly 50,000 books, including old and rare manuscript...up here. // To be built at the National Ayurveda I...be one of the biggest ayurveda libraries in India....l books, journals and research papers and provide ...
Other Medicine News:Health News:Big Brother to the Rescue 2Health News:Binge Drinking Excessive Among Less Educated Middle-aged Women 2Health News:New Software to Help Patients 2
(Date:5/8/2008)...l, Inc., the largest,privately held spinal implant... in motion preservation technology, today announce...Cervical Artificial Disc IDE study. The,SECURE(R)-... the spine in,order to alleviate pain and restore ...ent of symptomatic cervical disc disease. A total ...
(Date:5/8/2008)...-- Alpharma Inc. (NYSE: ALO ),a global specialty...rom,clinical trials that showed ALO-01 (EMBEDA(TM)...red naltrexone hydrochloride) capsules,demonstrate...ability,alongside a promising safety and efficacy ...the 27th Annual Scientific Session of the American...
(Date:5/8/2008)...of the American Pain Society ... -- Patients treated with lacosamide,demonstrated ...in (DNP),compared to placebo-treated patients, ac...ng of the American Pain Society (APS) in Tampa, Fl...f a diabetic neuropathic,pain treatment providing ...
(Date:5/8/2008)... Clinicians Concerned About Systemic...May 8 /- Alpharma Inc. (NYS...al company, announced today that two,studies to be...annual,meeting demonstrate the efficacy, tolerabil...ma Pharmaceuticals, FLECTOR(R) Patch (diclofenac e...
Breaking Medicine Technology:Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 2Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 3Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 4Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 5Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 6Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session 7New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 2New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 3New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 2Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 3Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 4Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 5Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 6Data Show FLECTOR(R) Patch Yields Significant Pain Reduction for Acute Strains, Sprains and Contusions 7D1 Sports Training Facilities Adopt TurfAide 28TM 29 Antimicrobial to New Synthetic Turf Fields from AstroTurf 28R 29 357 1D1 Sports Training Facilities Adopt TurfAide 28TM 29 Antimicrobial to New Synthetic Turf Fields from AstroTurf 28R 29 357 2Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 354 1Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic 354 2PREOS 28R 29 Granted U S Orphan Drug Status for Treatment of Hypoparathyroidism 1777 1PREOS 28R 29 Granted U S Orphan Drug Status for Treatment of Hypoparathyroidism 1777 2PREOS 28R 29 Granted U S Orphan Drug Status for Treatment of Hypoparathyroidism 1777 3FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 1FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 2FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 3FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 4FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 5FDA Approves Expanded Labeling for Campath 28R 29 to Include First line Treatment for Leading Form of Adult Leukemia 1774 6
...SBS, CALGARY, June 20, 2007 /PRNewswire-FirstCall/...ny developing a portfolio of,therapeutic proteins ...nounced that it will be presenting a scientific po...of the American Diabetes,Association (ADA) in Chic...omplishments in the development of a highly-scalab...
...sored Investor Briefing and Webcast to Follow,Pres...e-FirstCall/ -- Biodel,Inc. today announced plans ... candidate, VIAject(TM), at the 67th Annual Americ... to be held in,Chicago, June 22 through June 26. ,...lace on June 22,from 4:15 - 6:15pm CST, a summary ...
Other Medicine Technology:SemBioSys to present new data at American Diabetes Association,annual meeting 2SemBioSys to present new data at American Diabetes Association,annual meeting 3Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 2Biodel Inc. to Present VIAject Clinical Progress at the 2007,American Diabetes Association Meeting 3
MIS Tibial Stylus
Ascent™ Anterior Referencing Femoral Instrument Case
The Lineage acetabular system with ceramic liners uses sophisticated manufacturing methods and materials to minimize wear debris generation.
Link All-Poly acetabular cups for cement.
Medicine Products: